Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 3/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4235396 | 0.91 | AQP1 (0.54) | AQP1HTR2CHTR2AHTR2BMAPK14 | |
| SCHEMBL4235683 | 0.88 | AQP1 (0.71) | AQP1HTR2CHTR2AHTR2BEZH2 | |
| SCHEMBL4232160 | 0.88 | AQP1 (0.51) | AQP1MAPK14DPP4SLC6A2SLC6A4 | |
| SCHEMBL4235064 | 0.86 | AQP1 (0.54) | AQP1DPP4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4223618 | 0.85 | AQP1 (0.45) | AQP1DPP4MAOBSLC6A2SLC6A4 | |
| SCHEMBL4232174 | 0.85 | AQP1 (0.67) | AQP1HTR2CHTR2AHTR2BEZH2 | |
| SCHEMBL4226797 | 0.83 | AQP1 (0.52) | AQP1HTR2ADPP4SLC6A2SLC6A4 | |
| SCHEMBL4230236 | 0.82 | AQP1 (0.57) | AQP1HTR2CHTR2AHTR2BEZH2 | |
| SCHEMBL4222410 | 0.82 | AQP1 (0.60) | AQP1HTR2CHTR2AHTR2BMAPK14 | |
| SCHEMBL4220623 | 0.82 | AQP1 (0.54) | AQP1HTR2AEZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1998764-A2 | METHODS FOR TREATING COGNITIVE AND OTHER DISORDERS | Wyeth a Corporation of the State of Delaware (US) | 2008-12-10 | — | — | EP | claimed |
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | claimed |
| US-7396857-B2 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2008-07-08 | — | — | US | claimed |
| EP-1879569-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | Wyeth (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1874292-A2 | METHODS FOR MODULATING BLADDER FUNCTION | Wyeth (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1871355-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | Wyeth (US) | 2008-01-02 | — | — | EP | claimed |
| EP-1871356-A1 | DIHYDROBENZOFURAN DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | claimed |
| EP-1871354-A1 | TREATMENT OF PAIN | Wyeth (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2007112065-A2 | METHODS FOR TREATING COGNITIVE AND OTHER DISORDERS | WYETH (US) | 2007-10-04 | — | — | WO | claimed |
| US-20070225334-A1 | Methods for treating cognitive and other disorders | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| US-20060258712-A1 | Methods for modulating bladder function | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258739-A1 | Dihydrobenzofuran derivatives and uses therof | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| WO-2006116221-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116170-A1 | DIHYDROBENZOFURAN DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116149-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116169-A2 | METHODS FOR MODULATING BLADDER FUNCTION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116171-A1 | TREATMENT OF PAIN | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225334-A1 | Methods for treating cognitive and other disorders | CHAT, COMT, ACHE | AQP1 1312/4885HTR2C 25/4885HTR2A 32/4885 |
| US-20060258739-A1 | Dihydrobenzofuran derivatives and uses therof | HTR1F, HTR2C, HTR3D | AQP1 3184/4885HTR2C 2/4885HTR2A 9/4885 |
| US-20060258712-A1 | Methods for modulating bladder function | PDE3A, PDE3B, PDE2A | AQP1 137/4885HTR2C 1494/4885HTR2A 1749/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | AQP1 1105/4885HTR2C 1/4885HTR2A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.